nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

10.01.2022 | COVID-19 | Original Article Zur Zeit gratis

Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19

verfasst von: Derya Ozturk, Nesrin Gareayaghi, Ceren Atasoy Tahtasakal, Mustafa Calik, Ertugrul Altinbilek

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

CoronaVac, an inactivated whole-virion vaccine against COVID-19, has been shown to be safe with acceptable antibody responses by various clinical trials.

Aims

The objective was to investigate the post-vaccination antibody levels of both symptomatic and asymptomatic healthcare workers with or without the diagnosis of COVID-19 in an emergency department (ED) of a hospital serving as a pandemic hospital.

Methods

This single-centred, prospective study was conducted on 86 participants who were working as nurse or doctor in the ED. The volunteers were older than 18 years and either positive or negative for either computed tomography (CT), real-time reverse transcription polymerase chain reaction (qRT-PCR), or both. Thirty days after the second dose of CoronaVac (3 µg), the antibody levels were chemiluminescent microparticle immunoassay.

Results

Mean age of all participants were 33.1 ± 9.1 years. The antibody levels in the qRT-PCR( +) and CT( +) groups were significantly higher than the qRT-PCR( −) and CT( −) groups, respectively (p < 0.05). In the CT( +)/qRT-PCR( +) group, the antibody level was significantly higher than the CT( −)/qRT-PCR( −) and CT( −)/qRT-PCR( +) or CT( +)/qRT-PCR( −) group (p < 0.05). On the other hand, antibody levels in the hospitalized group were significantly higher than in the non-hospitalized group (p < 0.05). A significant positive correlation was observed between the time elapsed after vaccination and antibody levels of the participants (r = 0.343; p = 0.000).

Conclusion

In conclusion, antibody responses of recovered patients COVID-19 diagnosed by both CT and qRT-PCR were much robust than the patients diagnosed by either one of the techniques or undiagnosed/disease-free participants suggesting that severity of the disease likely contributes to the antibody responses after vaccination with CoronaVac.

Tatar M, Shoorekchali JM, Faraji MR, Wilson FA (2021) International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis? J Glob Health 11:03086. https://doi.org/10.7189/jogh.11.03086CrossRefPubMedPubMedCentral

Black M, Ford J, Lee A (2021) Vaccination against COVID-19 and inequalities - avoiding making a bad situation worse. Public Health Pract (Oxf) 2:100101. https://doi.org/10.1016/j.puhip.2021.100101CrossRef

Alobo M (2021) Strengthened health systems are needed to tackle COVID-19 in Africa. Nat Med 27(7):1126–1127. https://doi.org/10.1038/s41591-021-01395-6CrossRefPubMed

Kirkcaldy RD, King BA, Brooks JT (2020) COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA 323(22):2245–2246. https://doi.org/10.1001/jama.2020.7869CrossRefPubMedPubMedCentral

Sewell HF, Agius RM, Kendrick D, Stewart M (2020) Covid-19 vaccines: delivering protective immunity. BMJ 371:m4838. https://doi.org/10.1136/bmj.m4838CrossRefPubMed

Suthar MS, Zimmerman MG, Kauffman RC et al (2020) Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 1(3)

Yan ZP, Yang M, Lai CL (2021) COVID-19 Vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals (Basel) 14(5). https://doi.org/10.3390/ph14050406

Organization WH (2021) Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization, Genova, Switzerland

Kyriakidis NC, López-Cortés A, González EV et al (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6(1):28. https://doi.org/10.1038/s41541-021-00292-wCrossRefPubMedPubMedCentral

10.

Tanriover MD, Doğanay HL, Akova M et al (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398(10296):213–222. https://doi.org/10.1016/s0140-6736(21)01429-xCrossRefPubMedPubMedCentral

11.

Yu ED, Grifoni A, Sutherland A et al (2021) Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines (Basel) 9(5). https://doi.org/10.3390/vaccines9050426

12.

Al Kaabi N, Zhang Y, Xia S et al (2021) Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 326(1):35–45. https://doi.org/10.1001/jama.2021.8565CrossRefPubMed

13.

Awadasseid A, Wu Y, Tanaka Y, Zhang W (2021) Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 17(1):8–19. https://doi.org/10.7150/ijbs.52569CrossRefPubMedPubMedCentral

14.

Iversen PL, Bavari S (2021) Inactivated COVID-19 vaccines to make a global impact. Lancet Infect Dis 21(6):746–748. https://doi.org/10.1016/s1473-3099(21)00020-7CrossRefPubMedPubMedCentral

15.

Seow J, Graham C, Merrick B et al (2020) Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5(12):1598–1607. https://doi.org/10.1038/s41564-020-00813-8CrossRefPubMedPubMedCentral

16.

Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929–936. https://doi.org/10.1056/NEJMoa2001191CrossRefPubMedPubMedCentral

17.

Gao Q, Bao L, Mao H et al (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369(6499):77–81. https://doi.org/10.1126/science.abc1932CrossRefPubMed

18.

Wang H, Zhang Y, Huang B et al (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713–21.e9. https://doi.org/10.1016/j.cell.2020.06.008CrossRefPubMedPubMedCentral

19.

Mohandas S, Yadav PD, Shete-Aich A et al (2021) Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience 24(2):102054. https://doi.org/10.1016/j.isci.2021.102054

20.

Ganneru B, Jogdand H, Daram VK et al (2021) Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience 24(4):102298. https://doi.org/10.1016/j.isci.2021.102298

21.

Zhang Y, Zeng G, Pan H et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21(2):181–192. https://doi.org/10.1016/s1473-3099(20)30843-4CrossRefPubMed

22.

Wu Z, Hu Y, Xu M et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21(6):803–812. https://doi.org/10.1016/s1473-3099(20)30987-7CrossRefPubMedPubMedCentral

23.

Logunov DY, Dolzhikova IV, Shcheblyakov DV et al (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275):671–681. https://doi.org/10.1016/s0140-6736(21)00234-8CrossRefPubMedPubMedCentral

24.

Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389CrossRefPubMed

25.

Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577CrossRefPubMed

26.

Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://doi.org/10.1016/s0140-6736(20)32661-1CrossRefPubMedPubMedCentral

27.

Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–201. https://doi.org/10.1056/NEJMoa2101544

28.

Jara A, Undurraga EA, González C et al (2021) Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 385(10):875–884. https://doi.org/10.1056/NEJMoa2107715CrossRefPubMed

29.

Lim WW, Mak L, Leung GM et al (2021) Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2(9)

30.

Pan H, Wu Q, Zeng G et al (2021) Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18–59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv. 2021:2021.07.23.21261026. https://doi.org/10.1101/2021.07.23.21261026

31.

Khoury DS, Cromer D, Reynaldi A et al (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27(7):1205–1211. https://doi.org/10.1038/s41591-021-01377-8CrossRefPubMed

32.

Koch T, Mellinghoff SC, Shamsrizi P (2021) Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel) 9(3). https://doi.org/10.3390/vaccines9030238

33.

Earle KA, Ambrosino DM, Fiore-Gartland A et al (2021) Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39(32):4423–4428. https://doi.org/10.1016/j.vaccine.2021.05.063CrossRefPubMedPubMedCentral

34.

Grifoni A, Weiskopf D, Ramirez SI et al (2020) Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181(7):1489–501.e15. https://doi.org/10.1016/j.cell.2020.05.015CrossRefPubMedPubMedCentral

35.

Sekine T, Perez-Potti A, Rivera-Ballesteros O et al (2020) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183(1):158–68.e14. https://doi.org/10.1016/j.cell.2020.08.017CrossRefPubMedPubMedCentral

Titel: Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19
verfasst von: Derya Ozturk
Nesrin Gareayaghi
Ceren Atasoy Tahtasakal
Mustafa Calik
Ertugrul Altinbilek
Publikationsdatum: 10.01.2022
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 6/2022
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-021-02883-x

Papers perpetually in press: intellect left to rot

Brief Report

A contemporary series of surgical outcomes following subtotal colectomy and/or completion proctectomy for management of inflammatory bowel disease

Original Article

Duration of antibody responses following severe acute respiratory syndrome coronavirus 2 infection

Open Access
COVID-19
Brief Report

The implication of BRAF mutation in advanced colorectal cancer

Open Access
Original Article

Assessment of the workload and financial burden of Bosniak IIF renal cyst surveillance in a tertiary referral hospital

Original Article

Comparison of ultrasound-guided pulsed radiofrequency versus steroid injection in the treatment of carpal tunnel syndrome

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Antibiotika bei Bakteriämie – 7 versus 14 Tage

21.01.2025
Sepsis
Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

"Die Erektionsstörung ist keine isolierte Erkrankung"

21.01.2025
Erektile Dysfunktion
Podcast

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

20.01.2025
Koronare Herzerkrankung
Nachrichten

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

20.01.2025
Chronische Herzinsuffizienz
Nachrichten

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19